The use of PET in Alzheimer disease (original) (raw)

• Brookmeyer, R., Johnson, E., Ziegler-Graha, K. & Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186–191 (2007).
  Article PubMed Google Scholar
• Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).
  Article PubMed Google Scholar
• Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 430, 631–639 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 6, 734–746 (2007).
  Article PubMed Google Scholar
• Herholz, K., Carter, S. F. & Jones, M. Positron emission tomography imaging in dementia. Br. J. Radiol. 80 (Spec. No. 2), S160–S167 (2007).
  Article PubMed Google Scholar
• Small, G. W. et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 7, 161–172 (2008).
  Article PubMed PubMed Central Google Scholar
• Mosconi, L. et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811–822 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Mosconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486–510 (2005).
  Article CAS PubMed Google Scholar
• Engler, H. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856–2866 (2006).
  Article PubMed Google Scholar
• Jagust, W., Reed, B., Mungas, D., Ellis, W. & Decarli, C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871–877 (2007).
  Article CAS PubMed Google Scholar
• Drzezga, A. et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J. Nucl. Med. 46, 1625–1632 (2005).
  CAS PubMed Google Scholar
• Drzezga, A. et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30, 1104–1113 (2003).
  Article PubMed Google Scholar
• Mosconi, L. et al. Early detection of Alzheimer's disease using neuroimaging. Exp. Gerontol. 42, 129–138 (2007).
  Article PubMed Google Scholar
• Minoshima, S., Foster, N. L. & Kuhl, D. E. Posterior cingulate cortex in Alzheimer's disease. Lancet 344, 895 (1994).
  Article CAS PubMed Google Scholar
• Minoshima, S. et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85–94 (1997).
  Article CAS PubMed Google Scholar
• Schöll, M. et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2009.08.016.
  Article PubMed CAS Google Scholar
• Reiman, E. M. et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284–289 (2004).
  Article CAS PubMed Google Scholar
• Small, G. W. et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942–947 (1995).
  Article CAS PubMed Google Scholar
• Reiman, E. M. et al. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 3334–3339 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Reiman, E. M. et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N. Engl. J. Med. 334, 752–758 (1996).
  Article CAS PubMed Google Scholar
• Pedersen, N. L., Gatz, M., Berg, S. & Johansson, B. How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann. Neurol. 55, 180–185 (2004).
  Article PubMed Google Scholar
• Järvenpää, T. et al. Regional cerebral glucose metabolism in monozygotic twins discordant for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 16, 245–252 (2003).
  Article PubMed CAS Google Scholar
• Virta, J. J. et al. Voxel-based analysis of cerebral glucose metabolism in mono- and dizygotic twins discordant for Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80, 259–266 (2009).
  Article CAS PubMed Google Scholar
• Mosconi, L. et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl Acad. Sci. USA 104, 19067–19072 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Braak, H., de Vos, R. A., Jansen, E. N., Bratzke, H. & Braak, E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 117, 267–285 (1998).
  Article CAS PubMed Google Scholar
• Perry, E. K., Perry, R. H., Blessed, G. & Tomlinson, B. E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 4, 273–277 (1978).
  Article CAS PubMed Google Scholar
• Rinne, J. O. et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 113–115 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Herholz, K., Weisenbach, S., Kalbe, E., Diederich, N. J. & Heiss, W. D. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 16, 1431–1434 (2005).
  Article CAS PubMed Google Scholar
• Paterson, D. & Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61, 75–111 (2000).
  Article CAS PubMed Google Scholar
• Kadir, A., Almkvist, O., Wall, A., Långström, B. & Nordberg, A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl.) 188, 509–520 (2006).
  Article CAS Google Scholar
• Horti, A. G., Gao, Y., Kuwabara, H. & Dannals, R. F. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. doi:10.1016/j.lfs.2009.02.029.
  Article CAS PubMed Google Scholar
• Sabri, O., Kendziorra, K., Wolf, H., Gertz, H. J. & Brust, P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 35 (Suppl. 1), S30–S45 (2008).
  Article CAS PubMed Google Scholar
• Pomper, M. G. et al. Synthesis and biodistribution of radiolabeled α7 nicotinic acetylcholine receptor ligands. J. Nucl. Med. 46, 326–334 (2005).
  CAS PubMed Google Scholar
• Toyohara, J. et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography. Ann. Nucl. Med. 23, 301–309 (2009).
  Article CAS PubMed Google Scholar
• Zubieta, J. K. et al. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 39, 275–287 (2001).
  Article CAS PubMed Google Scholar
• Cohen, R. M. et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-ε4 allele. Synapse 49, 150–156 (2003).
  Article CAS PubMed Google Scholar
• Reinikainen, K. J., Soininen, H. & Riekkinen, P. J. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J. Neurosci. Res. 27, 576–586 (1990).
  Article CAS PubMed Google Scholar
• Rinne, J. O., Sahlberg, N., Ruottinen, H., Nagren, K. & Lehikoinen, P. Striatal uptake of the dopamine reuptake ligand [11C]β-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50, 152–156 (1998).
  Article CAS PubMed Google Scholar
• Walker, Z. et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J. Neurol. Neurosurg. Psychiatry 73, 134–140 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• McKeith, I. et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 6, 305–313 (2007).
  Article PubMed Google Scholar
• Walker, Z. et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J. Neurol. Neurosurg. Psychiatry 78, 1176–1181 (2007).
  Article PubMed PubMed Central Google Scholar
• Kemppainen, N., Ruottinen, H., Någren, K. & Rinne, J. O. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 55, 205–209 (2000).
  Article CAS PubMed Google Scholar
• Tanaka, Y. et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med. 17, 567–573 (2003).
  Article PubMed Google Scholar
• Kemppainen, N. et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur. J. Neurosci. 18, 149–154 (2003).
  Article CAS PubMed Google Scholar
• Nordberg, A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain. Metab. Rev. 4, 303–328 (1992).
  CAS PubMed Google Scholar
• Kepe, V. et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl Acad. Sci. USA 103, 702–707 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Meltzer, C. C. et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 156, 1871–1878 (1999).
  CAS PubMed Google Scholar
• Jagust, W. Mapping brain β-amyloid. Curr. Opin. Neurol. 22, 356–361 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319 (2004).
  Article CAS PubMed Google Scholar
• Klunk, W. E. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598–10606 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ikonomovic, M. D. et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 1630–1645 (2008).
  Article PubMed PubMed Central Google Scholar
• Leinonen, V. et al. Assessment of β-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch. Neurol. 65, 1304–1309 (2008).
  Article PubMed Google Scholar
• Svedberg, M. M. et al. [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 54, 347–357 (2009).
  Article CAS PubMed Google Scholar
• Archer, H. A. et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann. Neurol. 60, 145–147 (2006).
  Article PubMed Google Scholar
• Kemppainen, N. M. et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67, 1575–1580 (2006).
  Article CAS PubMed Google Scholar
• Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446–452 (2006).
  Article CAS PubMed Google Scholar
• Price, J. C. et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 25, 1528–1547 (2005).
  Article CAS PubMed Google Scholar
• Rowe, C. C. et al. Imaging β-amyloid burden in aging and dementia. Neurology 68, 1718–1725 (2007).
  Article CAS PubMed Google Scholar
• Forsberg, A. et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456–1465 (2008).
  Article CAS PubMed Google Scholar
• Jack, C. R. Jr et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355–1365 (2009).
  Article PubMed PubMed Central Google Scholar
• Kemppainen, N. M. et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68, 1603–1606 (2007).
  Article CAS PubMed Google Scholar
• Pike, K. E. et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837–2844 (2007).
  Article PubMed Google Scholar
• Okello, A. et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73, 754–760 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wolk, D. A. et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 65, 557–568 (2009).
  Article PubMed PubMed Central Google Scholar
• Lowe, V. J. et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 50, 878–886 (2009).
  Article PubMed Google Scholar
• Forsberg, A. et al. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr. Alzheimer Res. doi:10.2174/1567210198607192050.
• Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59, 512–519 (2006).
  Article CAS PubMed Google Scholar
• Koivunen, J. et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 26, 378–383 (2008).
  Article CAS PubMed Google Scholar
• Edison, P. et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68, 501–508 (2007).
  Article CAS PubMed Google Scholar
• Landau, S. M. et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2009.07.002.
  Article PubMed Google Scholar
• Grimmer, T. et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol. Aging 30, 1902–1909 (2008).
  Article PubMed CAS Google Scholar
• Villemagne, V. L. et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688–1697 (2008).
  Article CAS PubMed Google Scholar
• Drzezga, A. et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487–1494 (2009).
  Article CAS PubMed Google Scholar
• Reiman, E. M. et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 6820–6825 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Scheinin, N. M. et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 73, 1186–1192 (2009).
  Article CAS PubMed Google Scholar
• Edison, P. et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79, 1331–1338 (2008).
  Article CAS PubMed Google Scholar
• Johansson, A. et al. [11C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat. Disord. 14, 345–347 (2008).
  Article CAS PubMed Google Scholar
• Maetzler, W. et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39, 1027–1033 (2008).
  Article PubMed Google Scholar
• Drzezga, A. et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39, 619–633 (2008).
  Article PubMed Google Scholar
• Engler, H. et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging 35, 100–106 (2008).
  Article PubMed Google Scholar
• Gomperts, S. N. et al. Imaging amyloid deposition in Lewy body diseases. Neurology 71, 903–910 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, K. A. et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 62, 229–234 (2007).
  Article PubMed Google Scholar
• Aizenstein, H. J. et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509–1517 (2008).
  Article PubMed PubMed Central Google Scholar
• Small, G. W. et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652–2663 (2006).
  Article CAS PubMed Google Scholar
• Waragai, M. et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J. Neurol. Sci. 285, 100–108 (2009).
  Article PubMed Google Scholar
• Rowe, C. C. et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129–135 (2008).
  Article CAS PubMed Google Scholar
• Tolboom, N. et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J. Nucl. Med. 50, 191–197 (2009).
  Article PubMed Google Scholar
• Thompson, P. W. et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem. 109, 623–630 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Shoghi-Jadid, K. et al. Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24–35 (2002).
  Article PubMed Google Scholar
• Walsh, D. M. & Selkoe, D. J. Aβ oligomers—a decade of discovery. J. Neurochem. 101, 1172–1184 (2007).
  Article CAS PubMed Google Scholar
• Cagnin, A. et al. In-vivo measurement of activated microglia in dementia. Lancet 358, 461–467 (2001).
  Article CAS PubMed Google Scholar
• Okello, A. et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72, 56–62 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wiley, C. A. et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol. 66, 60–67 (2009).
  Article PubMed PubMed Central Google Scholar
• Hirsch-Reinshagen, V., Burgess, B. L. & Wellington, C. L. Why lipids are important for Alzheimer disease? Mol. Cell Biochem. 326, 121–129 (2009).
  Article CAS PubMed Google Scholar
• Kadir, A. et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol. Aging 29, 1204–1217 (2008).
  Article CAS PubMed Google Scholar
• Bohnen, N. I. et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 76, 315–319 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kuhl, D. E. et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol. 48, 391–395 (2000).
  Article CAS PubMed Google Scholar
• Kaasinen, V. et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 22, 615–620 (2002).
  Article CAS PubMed Google Scholar
• Shinotoh, H. et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56, 408–410 (2001).
  Article CAS PubMed Google Scholar
• Kadir, A. et al. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl.) 191, 1005–1014 (2007).
  Article CAS Google Scholar
• Ellis, J. R. et al. Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. Psychopharmacology (Berl.) 202, 79–91 (2009).
  Article CAS Google Scholar
• Diehl-Schmid, J. et al. Longitudinal changes of cerebral glucose metabolism in semantic dementia. Dement. Geriatr. Cogn. Disord. 22, 346–351 (2006).
  Article CAS PubMed Google Scholar
• Diehl-Schmid, J. et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol. Aging 28, 42–50 (2007).
  Article CAS PubMed Google Scholar
• Dickerson, B. C. & Sperling, R. A. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2, 348–360 (2005).
  Article PubMed PubMed Central Google Scholar
• Foster, N. L. et al. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement. 4 (Suppl. 1), S29–S36 (2008).
  PubMed Google Scholar
• Matthews, B., Siemers, E. R. & Mozley, P. D. Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am. J. Geriatr. Psychiatry 11, 146–159 (2003).
  Article PubMed Google Scholar
• Mega, M. S. et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 14, 63–68 (2001).
  CAS PubMed Google Scholar
• Stefanova, E. et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J. Neural Transm. 113, 205–218 (2006).
  Article CAS PubMed Google Scholar
• Tune, L. et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry 11, 169–177 (2003).
  Article PubMed Google Scholar
• Mega, M. S. et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomographic study. Arch. Neurol. 62, 721–728 (2005).
  Article PubMed Google Scholar
• Teipel, S. J. et al. Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl.) 187, 86–94 (2006).
  Article CAS Google Scholar
• Kadir, A. et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann. Neurol. 63, 621–631 (2008).
  Article CAS PubMed Google Scholar
• Smith, G. S. et al. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain 132, 392–401 (2009).
  Article PubMed PubMed Central Google Scholar
• Tuszynski, M. H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551–555 (2005).
  Article CAS PubMed Google Scholar
• Eriksdotter Jonhagen, M. et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, 246–257 (1998).
  Article CAS PubMed Google Scholar
• Lahiri, D. K. et al. The experimental Alzheimer's disease drug posiphen[(+)-phenserine] lowers amyloid-β peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther. 320, 386–396 (2007).
  Article CAS PubMed Google Scholar
• Marutle, A. et al. Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc. Natl Acad. Sci. USA 104, 12506–12511 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Razifar, P. et al. An automated method for delineating a reference region using masked volumewise principal-component analysis in 11C-PIB PET. J. Nucl. Med. Technol. 37, 38–44 (2009).
  Article PubMed Google Scholar
• Razifar, P., Ringheim, A., Engler, H., Hall, H. & Långström, B. Masked-volume-wise PCA and “reference Logan” illustrate similar regional differences in kinetic behavior in human brain PET study using [11C]-PIB. BMC Neurol. 9, 2 (2009).
  Article PubMed PubMed Central Google Scholar
• Nordberg, A. Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol. 20, 398–402 (2007).
  Article CAS PubMed Google Scholar
• Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183–194 (2004).
  Article CAS PubMed Google Scholar
• Roivainen, A. et al. Biodistribution and blood metabolism of 1-11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET. J. Nucl. Med. 45, 2032–2039 (2004).
  CAS PubMed Google Scholar
• Nelissen, N. et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50, 1251–1259 (2009).
  Article CAS PubMed Google Scholar
• Verhoeff, N. P. et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584–595 (2004).
  PubMed Google Scholar
• Kudo, Y. et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48, 553–561 (2007).
  Article CAS PubMed Google Scholar
• Choi, S. R. et al. Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. J. Nucl. Med. 50, 1887–1894 (2009).
  Article CAS PubMed Google Scholar
• Nyberg, S. et al. Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur. J. Nucl. Med. Mol. Imaging 36, 1859–1863 (2009).
  Article PubMed PubMed Central Google Scholar